Not Yet Recruiting OBSERVATIONAL NCT07199010
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
A Multicenter, Non-interventional, Observational Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions
Non-small Lung Cancer
Interventions
Taletrectinib
Updated 1 time since 2025 Last updated: Sep 22, 2025 Started: Oct 31, 2025 Primary completion: Sep 30, 2027 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This observational or N/A phase trial investigates Non-small Lung Cancer and is currently actively recruiting participants. Innovent Biologics (Suzhou) Co. Ltd. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Innovent Biologics (Suzhou) Co. Ltd.
Data source: Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .